US2007232788A1PendingUtilityA1
Factor viii compositions and methods
Est. expiryOct 31, 2023(expired)· nominal 20-yr term from priority
A61K 38/00C07K 14/755
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides methods of increasing the half-life and/or specific activity of factor VIII. More specifically, the invention provides methods of increasing the half-life and/or specific activity of factor VIII by substituting one or more amino acids in the A2 domain. It further provides methods for producing such factor VIII mutants. The invention also provides polynucleotides encoding the mutant factor VIII, and methods of treating hemophilia using the polypeptides and polynucleotides of the invention.
Claims
exact text as granted — not AI-modified1 . A mutant factor VIII comprising an amino acid substitution at position Lys(466) and/or position Arg(471) and optionally at one or more positions selected from the group consisting of Lys(380), Arg(484), Tyr(487), Ser(488), Arg(489), Arg(490), His(497), His(499), Lys(523) and Lys(556), wherein the mutant factor VIII has procoagulant activity.
2 .- 32 . (canceled)Join the waitlist — get patent alerts
Track US2007232788A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.